Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The vascular endothelial growth factor (VEGF)‐mediated enhancement in vascular permeability is considered to be a major factor in tumor‐targeting delivery via the enhanced permeability and retention (EPR) effect. We previously reported that the silencing of the endothelial VEGF receptor (VEGFR2) by a liposomal siRNA system (RGD‐MEND) resulted in an enhanced intratumoral distribution of polyethylene glycol (PEG)‐modified liposomes (LPs) in a renal cell carcinoma, a type of hypervascularized cancer, although the inhibition of VEGF signaling would be expected to decrease the permeability of the tumor vasculature. We herein report that the enhancement in the intratumoral distribution of LPs by VEGFR2 inhibition was dependent on the vascular type of the tumor (stroma vessel type; SV and tumor vessel type; TV). In the case of TV‐type tumors (renal cell carcinoma and hepatocellular carcinoma), inhibiting VEGFR2 improved intratumoral distribution, while no effect was found in the case of SV‐type tumors (colorectal cancer). Moreover, through a comparison of the intratumoral distribution of LPs with a variety of physical properties (100 nm vs 400 nm, neutral vs negative vs positive), VEGFR2 inhibition was found to alter the tumor microenvironment, including heparan sulfate proteoglycans (HSPGs). In addition, the results regarding the effect of the size of nanoparticles indicated that VEGFR2 inhibition improved the penetration of nanoparticles through the vessel wall, but not via permeability, suggesting the involvement of an unknown mechanism. Our findings suggest that a combination of anti‐angiogenic therapy and delivery via the EPR effect would be useful in certain cases, and that altering the tumor microenvironment by VEGFR2 blockade has a drastic effect on the intratumoral distribution of nanoparticles. Graphical abstract Figure. No Caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Mechanisms and regulation of endothelial VEGF receptor signalling
Simons, M., Gordon, E., & Claesson-Welsh, L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.87 · Cited by 1,498 · cited 1×
“As VEGFR2 and HSPGs coordinately facilitate the development of angiogenesis [56], the inhibition of VEGFR2 by siVR2 altered the expression of some HSPGs.”
BackgroundChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101 · cited 1×
“reported that the improvement in the delivery of nanoparticles via VEGFR2 inhibition by the antibody DC101 was dependent on the size of nanoparticles by comparing the effect with Abraxane (12 nm) and Doxil (100 nm) [19].”
MethodChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · cited 1×
“, found that the amount of collagen I was inversely correlated to the proportion of perfused vessels [46].”
BackgroundCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · cited 1×
“We focused on remodeling the extracellular matrix (ECM) via VEGFR2 inhibition because the degradation of collagen and hyaluronic acid to low molecular weight compounds by enzymes also enhanced the EPR-based delivery of nanoparticles [8-10].”
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424 · cited 1×
“VEGF acceleration played an important role in the abnormality of the tumor vasculature [48].”
BackgroundInfluence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Sung, M. M. H., Tam, Y. K., & Cullis, P. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.059 · Cited by 366
Wessel, F., Winderlich, M., Holm, M., Frye, M., Rivera-Galdos, R., Vockel, M., Linnepe, R., Ipe, U., Stadtmann, A., Zarbock, A., et al. (2014) · Nature Immunology · doi:10.1038/ni.2824 · Cited by 354
Cited by
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
Zhang, M., Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Liu, Y., Liu, X., Su, K., & Shi, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.033 · Cited by 274
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Yang, S., & Gao, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.004 · Cited by 256
Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy
Muntimadugu, E., Kommineni, N., & Khan, W. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.010 · Cited by 82
Metadata
- Authors
- Yamamoto, S., Kato, A., Sakurai, Y., Hada, T., & Harashima, H.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 251
- Pages
- 1-10
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2586604110
- Cited by
- 46
- References
- 12
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. https://app.cochat.ai/papers/10.1016/j.jconrel.2017.02.010
- The paper
- Yamamoto, S., Kato, A., Sakurai, Y., Hada, T., & Harashima, H. (2017). Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2017.02.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.